Xiangdong Cheng
Xiangdong Cheng
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer | Gastric Cancer Stage | Not yet recruiting | Phase 3 | 2025-07-16 | NCT07068516 | |
| QL1706 Combined With SOX Used in Theperioperative Treatment | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2025-06-17 | NCT06766305 | |
| Study of IBI363 in Patients with Advanced First-line Gastric Cancer | IBI363 + Chemotherapy | Recruiting | Phase 1 | 2024-11-20 | NCT06610799 | |
| A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established | Abdominal Neoplasms, Neoplasms by Site, neoplasm | Recruiting | Not stated | 2024-09-26 | NCT06614179 | |
| Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Not yet recruiting | Phase 2 | 2024-04-19 | NCT06374901 |